Earnings Call Transcripts

Access detailed transcripts and key takeaways from company earnings calls

All Earnings Calls

ZBH November 5, 2025

Zimmer Biomet Q3 2025 Earnings Call - Innovation Cycle Drives US Growth Amid Emerging Market Challenges

Zimmer Biomet reported a 5% organic constant currency revenue growth in Q3 2025, with a notable acceleration in the US business to 5.6%, marking the best growth since mid-2023. The company highlighted...

  • Zimmer Biomet achieved 5% organic constant currency revenue growth in Q3 2025, led by 5.6% growth in the US market—the strongest US performance since mid-2023.
  • Late-quarter disruptions including distributor order cancellations in Eastern Europe, Middle East, and Latin America, as well as softness in restorative therapies, negatively impacted growth by nearly 120 basis points.
  • Strong product adoption in US knees with Persona Osteotide cementless knee representing nearly 30% of US total knee implants, targeting over 50% penetration by end of 2027.
  • +10 more takeaways
ESTA November 5, 2025

Establishment Labs Q3 2025 Earnings Call - First Positive EBITDA Quarter Fueled by U.S. Market Momentum

Establishment Labs reported a strong Q3 2025 with a 34% revenue jump to $53.8 million, driven primarily by a booming U.S. business that surged 16% sequentially despite a traditionally slow quarter. Th...

  • Establishment Labs grew global revenue by 34% in Q3 2025 to $53.8 million, including $11.9 million in the U.S.
  • The company achieved its first positive adjusted EBITDA quarter at $1.2 million, beating prior expectations.
  • Gross profit margin exceeded 70% (70.1%) for the first time, driven by higher margin sales in the U.S.
  • +13 more takeaways
DDD November 5, 2025

3D Systems Q3 2025 Earnings Call - Strategic Pivot Amid Revenue Decline Driven by Tariff-Induced Capex Uncertainty

3D Systems reported a challenging Q3 2025 with revenue declining 13.8% year-over-year to $91.2 million, reflecting muted capital expenditures across 3D printing OEMs amid tariff uncertainties. The com...

  • Q3 2025 revenue declined 13.8% year-over-year to $91.2 million, driven by continued soft capital expenditures from customers due to tariff uncertainties.
  • Company closed sales of non-core software assets Octane and 3Dexter to focus on proprietary technologies, with a modest financial impact expected in Q4.
  • Aggressive cost reduction initiatives underway targeting over $50 million in annualized savings by year-end, including organizational optimization and facility consolidations extending into early 2026.
  • +10 more takeaways
OI November 5, 2025

O-I Glass Q3 2025 Earnings Call - Profit Margins Surge Amid Volume Declines and Strategic Transformation

O-I Glass reported a robust third quarter with adjusted earnings per share of $0.48, surpassing both prior year figures and company estimates. While net sales remained stable at $1.7 billion, shipment...

  • O-I Glass achieved adjusted EPS of $0.48 in Q3 2025, exceeding prior year and internal forecasts.
  • Net sales held steady at $1.7 billion despite a 5% decline in shipment volumes, reflecting mixed consumer demand trends.
  • Volumes decreased due to weak beer and wine categories, partially offset by growth in non-alcoholic beverages, food, and RTDs.
  • +17 more takeaways
GDRX November 5, 2025

GoodRx Q3 2025 Earnings Call - Strategic Expansion of Manufacturer Solutions and Pharmacy Counter Integration

GoodRx delivered a solid Q3 2025 highlighted by a 54% year-over-year revenue growth in its manufacturer solutions segment, bolstered by new partnerships with Novo Nordisk and Amgen to provide direct-t...

  • GoodRx achieved 54% year-over-year revenue growth in manufacturer solutions, driven by expanded brand partnerships and new deals.
  • The company closed deals with Novo Nordisk and Amgen to offer significant cash price discounts on Ozempic, Wegovy, and Repatha, enhancing direct-to-consumer access.
  • Prescription transaction revenue declined 9% due to the completed Rite Aid pharmacy closures and reduced volume with an integrated savings PBM partner.
  • +13 more takeaways
LIVN November 5, 2025

LivaNova Q3 2025 Earnings Call - Strong Organic Growth and Strategic Investments Drive Margin Expansion

LivaNova reported a robust third quarter in 2025, delivering 13% organic revenue growth led by cardiopulmonary momentum and epilepsy segment advances across all regions. The company raised its full-ye...

  • LivaNova achieved 13% organic revenue growth in Q3 2025, driven primarily by cardiopulmonary and epilepsy segments.
  • Cardiopulmonary revenue increased 16% to $203 million, bolstered by over 20% growth in heart-lung machine (HLM) sales.
  • ESSENCE heart-lung machine placements accelerated in developed markets with a commercial launch in China begun in August, expected to materially contribute in 2026.
  • +13 more takeaways
SHOO November 5, 2025

Steve Madden Ltd Q3 2025 Earnings Call - Tariff Challenges Temper Growth Despite Strong Brand Momentum

Steve Madden’s third quarter 2025 results reveal a business navigating intense tariff-induced disruptions with a mix of resilience and strategic pivoting. New tariffs on Chinese imports caused wholesa...

  • Q3 revenue increased 6.9% to $667.9 million, but fell 14.8% excluding Kurt Geiger acquisition.
  • Wholesale revenue declined 10.7%, driven by a 19% drop excluding Kurt Geiger; tariff-related order cuts and shipment delays were key factors.
  • Direct-to-consumer (DTC) revenue surged 76.6%, or 1.5% excluding Kurt Geiger, reflecting strong digital engagement.
  • +13 more takeaways
BRLT November 5, 2025

Brilliant Earth Q3 2025 Earnings Call - Engagement Rings Rebound and Fine Jewelry Surges Amid Industry Headwinds

Brilliant Earth marked its 20th anniversary with strong third-quarter results, reporting a 10% year-over-year net sales increase that beat expectations. The company saw a key inflection point with eng...

  • Brilliant Earth achieved 10.4% year-over-year net sales growth in Q3 2025, surpassing guidance.
  • Engagement ring bookings, previously soft after a market normalization, returned to year-over-year growth signaling a bridal recovery.
  • Wedding and anniversary band bookings reached their highest ever, with strong growth in men's and women's collections.
  • +12 more takeaways
TFPM November 5, 2025

Triple Flag Precious Metals Q3 2025 Earnings Call - Record Cash Flows Amid Strategic Royalty Acquisitions and Strong Gold Prices

Triple Flag Precious Metals delivered a standout Q3 2025, boasting record adjusted EBITDA of $79 million driven by 27,000 gold equivalent ounces (GEOs) and an operating cash flow per share of 39 cents...

  • Triple Flag achieved record adjusted EBITDA of $79 million in Q3 2025, driven by 27,000 GEOs and strong gold prices.
  • Operating cash flow per share rose over 25% year-over-year, reaching 39 cents US, reflecting robust cash generation.
  • The company is on track to meet or exceed the midpoint to high end of its 2025 GEO production guidance.
  • +11 more takeaways
TBLA November 5, 2025

Taboola Q3 2025 Earnings Call - Realize Platform Gains Traction, Driving Confident Outlook and Share Buybacks

Taboola reported a strong Q3 2025, beating guidance across key metrics with revenues of $497 million and an adjusted EBITDA margin above 27%. The company highlighted an inflection point in its Realize...

  • Taboola exceeded high-end Q3 2025 guidance with $497M revenue and $48M adjusted EBITDA, delivering strong 27% EBITDA margin.
  • The AI-powered Realize platform reached an inflection point, helping advertisers achieve higher ROI and fueling growth confidence.
  • Number of scaled advertisers (spending $100K+) rose 4% to 2,064, while average revenue per scaled advertiser grew 11%, key drivers for ex-TAC gross profit growth.
  • +7 more takeaways